ARCHIVES

In Brief: Bristol Has Change Of Heart, Agrees To Supply NCI With VP-16 Free For Group C Distribution

This article is from The Cancer Letter archive.

Vol. 08 No. 29 | July 16, 1982

Download PDF Visit The Full Archive

Related Articles

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

March 29, 2013

DES Study Indicates Threat If Vaginal Cancer May Not Be Serious

November 15, 1974

Drug Marketing; Zeneca sues Eli Lilly, Claiming Misleading Promotion of Evista

March 12, 1999

Burton’s Clinic Reported Operating In Spite of Closure

December 13, 1985

Perifosine Increases PFS In Phase II Study

December 30, 2011

Patents: Myriad Patents Spectrometry To Assess DNA Polymorphisms

March 5, 1999